IsoRay initiates shipment of GliaSite radiation therapy system

April 01, 2017

The news comes as the Company is moving forward to achieve FDA clearance of liquid Cesium-131 for use with the GliaSite? radiation system. IsoRay is the exclusive manufacturer of Cesium-131 for cancer treatment. In its current form, the pioneering brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years. In other developments, CEO Babcock revealed that discussions are already underway regarding the application of Cesium-131 for treating cancers in other body sites including breast and esophageal cancers.

Babcock says he views the latest developments as just the beginning of important benefits from GliaSite? for the company, too. "We expect GliaSite? to be a tremendous revenue generator. It is my sense that it will fuel other important opportunities for IsoRay's growth and expansion."

IsoRay holds exclusive worldwide distribution rights for the GliaSite? radiation therapy system as well as exclusive worldwide licensing rights to Iotrex?, a liquid iodine radiation for use in brain cancer treatment. Prior to the Company's acquisition of the GliaSite? technology, approximately 500 GliaSite? cases were performed annually at some 40 hospitals worldwide.

The GliaSite? system has established reimbursement for both in-patient and out-patient settings. In addition to its CMS codes, Cesium-131 is FDA-cleared in seed form for the treatment of prostate cancer, lung cancer, ocular melanoma cancer, brain cancer, colorectal cancer, gynecologic cancer, and head and neck cancer and other cancers throughout the body.

Source IsoRay, Inc.,

©2017 -